Abstract
Since the discovery of stem cells, scientists have invested tremendous effort in establishing in vitro culture conditions in order to maintain the self-renewal and efficient proliferative capabilities of stem cells by manipulating a variety of growth factors. Fibroblast growth factor (FGF) is one of the most common growth factors used to expand stem cells, including human embryonic stem (hES) cells and several tissue type-specific stem cells. Moreover, it has been recently recognized that FGF is useful for culturing cancer stem cells derived from various types of human tumor tissues, such as brain and breast tumors. The molecular mechanisms underlying the control of stemness by FGF have remained elusive for a long time. The main signal transduction pathway initiated at the FGF receptors leads to the activation of Ras/ERK pathways via the control center FRS2α. Recent emerging evidence suggests that the FGF-ERK axis controls stemness via multiple modes of action. I would like to summarize current understanding of this subject from recent discoveries in this field.
Keywords: FRS2, adaptor, embryonic stem (ES) cells, iPS cells, trophoblast stem (TS) cells, neural stem cells
Current Stem Cell Research & Therapy
Title: Control of Stemness by Fibroblast Growth Factor Signaling in Stem Cells and Cancer Stem Cells
Volume: 4 Issue: 1
Author(s): Noriko Gotoh
Affiliation:
Keywords: FRS2, adaptor, embryonic stem (ES) cells, iPS cells, trophoblast stem (TS) cells, neural stem cells
Abstract: Since the discovery of stem cells, scientists have invested tremendous effort in establishing in vitro culture conditions in order to maintain the self-renewal and efficient proliferative capabilities of stem cells by manipulating a variety of growth factors. Fibroblast growth factor (FGF) is one of the most common growth factors used to expand stem cells, including human embryonic stem (hES) cells and several tissue type-specific stem cells. Moreover, it has been recently recognized that FGF is useful for culturing cancer stem cells derived from various types of human tumor tissues, such as brain and breast tumors. The molecular mechanisms underlying the control of stemness by FGF have remained elusive for a long time. The main signal transduction pathway initiated at the FGF receptors leads to the activation of Ras/ERK pathways via the control center FRS2α. Recent emerging evidence suggests that the FGF-ERK axis controls stemness via multiple modes of action. I would like to summarize current understanding of this subject from recent discoveries in this field.
Export Options
About this article
Cite this article as:
Gotoh Noriko, Control of Stemness by Fibroblast Growth Factor Signaling in Stem Cells and Cancer Stem Cells, Current Stem Cell Research & Therapy 2009; 4(1) . https://dx.doi.org/10.2174/157488809787169048
DOI https://dx.doi.org/10.2174/157488809787169048 |
Print ISSN 1574-888X |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3946 |

- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Nutrition Support of Patients Undergoing Hematopoietic Stem Cell Transplantation (HSCT)
Current Nutrition & Food Science Targeted Therapies in Non-Small Cell Lung Cancer: Proven Concepts and Unfulfilled Promises.
Current Cancer Drug Targets Haematopoietic Stem Cell Gene Therapy to Treat Autoimmune Disease
Current Stem Cell Research & Therapy Kinases as Drug Discovery Targets in Hematologic Malignancies
Current Molecular Medicine Heat Shock Proteins: A Potential Anticancer Target
Current Drug Targets Targeting mTOR Pathways in Human Malignancies
Current Pharmaceutical Design Antibody-Based Targeted Interventions for the Diagnosis and Treatment of Skin Cancers
Anti-Cancer Agents in Medicinal Chemistry Disaggregating Chaperones: An Unfolding Story
Current Protein & Peptide Science Multicolor-FISH Approaches for the Characterization of Human Chromosomes in Clinical Genetics and Tumor Cytogenetics
Current Genomics A Role for the Inflammatory Mediators Cox-2 and Metalloproteinases in Cancer Stemness
Anti-Cancer Agents in Medicinal Chemistry Perspectives in Breast and Ovarian Cancer Chemotherapy by Nanomedicine Approach: Nanoformulations in Clinical Research
Current Medicinal Chemistry Pathophysiology and Treatment of Nonfamilial Hyperparathyroidism
Recent Patents on CNS Drug Discovery (Discontinued) Wnt Signaling and Prostate Cancer
Current Drug Targets Using Nutrigenomics to Evaluate Apoptosis as a Preemptive Target in Cancer Prevention
Current Cancer Drug Targets Metal Containing Cytostatics and Their Interaction with Cellular Thiol Compounds Causing Chemoresistance
Anti-Cancer Agents in Medicinal Chemistry mTOR in Growth and Protection of Hypertrophying Myocardium
Cardiovascular & Hematological Agents in Medicinal Chemistry Targeting CSCs in Tumor Microenvironment: The Potential Role of ROS-Associated miRNAs in Tumor Aggressiveness
Current Stem Cell Research & Therapy Implications of Somatic Mutations in the AML1/RUNX1 Gene in Myelodysplastic Syndrome (MDS): Future Molecular Therapeutic Directions for MDS
Current Cancer Drug Targets Preclinical Development of New Therapy for Glycogen Storage Diseases
Current Gene Therapy Advancement in Infection Control of Opportunistic Pathogen (Aspergillus spp.): Adjunctive Agents
Current Pharmaceutical Biotechnology